Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
Altundag
Ozden
O
Altundag
Kadri
K
Boruban
Cem
C
Silay
Yavuz S
YS
D000970:Antineoplastic Agents / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002289:Carcinoma, Non-Small-Cell Lung / Q000378:metabolism* / Q000473:pathology; D000068579:Celecoxib; D002986:Clinical Trials as Topic; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D015232:Dinoprostone / Q000378:metabolism; D018450:Disease Progression; D000077143:Docetaxel; D066246:ErbB Receptors / Q000378:metabolism*; D000069347:Erlotinib Hydrochloride; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism* / Q000473:pathology; D011720:Pyrazoles / Q000494:pharmacology; D011799:Quinazolines / Q000494:pharmacology; D015398:Signal Transduction; D013449:Sulfonamides / Q000494:pharmacology; D043823:Taxoids / Q000494:pharmacology; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D011720:Pyrazoles; D011799:Quinazolines; D013449:Sulfonamides; D043823:Taxoids; D000077143:Docetaxel; D000069347:Erlotinib Hydrochloride; D051546:Cyclooxygenase 2; D066246:ErbB Receptors; D000068579:Celecoxib; D015232:Dinoprostone; D000077156:Gefitinib